Page last updated: 2024-09-04

cgs 26303 and Alloxan Diabetes

cgs 26303 has been researched along with Alloxan Diabetes in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Allen, TJ; Burrell, LM; Cao, Z; Casley, D; Cooper, ME; Davis, BJ; Johnston, CI; Lassila, M; Tikkanen, I; Tikkanen, T	1

Other Studies

1 other study(ies) available for cgs 26303 and Alloxan Diabetes

Article	Year
Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes. Journal of hypertension, 2002, Volume: 20, Issue:4 Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Aspartic Acid Endopeptidases; Atrial Natriuretic Factor; Blood Pressure; Bosentan; Diabetes Mellitus, Experimental; Drug Interactions; Endothelin Receptor Antagonists; Endothelin-Converting Enzymes; Heart; Kidney; Male; Metalloendopeptidases; Myocardium; Neprilysin; Organ Size; Organophosphonates; Protease Inhibitors; Rats; Rats, Sprague-Dawley; Renin; Sulfonamides; Tetrazoles	2002

Article

Year

Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes.

Journal of hypertension, 2002, Volume: 20, Issue:4

Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Aspartic Acid Endopeptidases; Atrial Natriuretic Factor; Blood Pressure; Bosentan; Diabetes Mellitus, Experimental; Drug Interactions; Endothelin Receptor Antagonists; Endothelin-Converting Enzymes; Heart; Kidney; Male; Metalloendopeptidases; Myocardium; Neprilysin; Organ Size; Organophosphonates; Protease Inhibitors; Rats; Rats, Sprague-Dawley; Renin; Sulfonamides; Tetrazoles

2002